loading page

Successful determination of imatinib dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction.
  • +2
  • Ryosuke Nakahara,
  • Takahiro Sumimoto,
  • Ryota Tanaka,
  • Masao Ogata,
  • Hiroki Itoh
Ryosuke Nakahara
Oita University Hospital
Author Profile
Takahiro Sumimoto
Oita University Hospital
Author Profile
Ryota Tanaka
Oita University Hospital
Author Profile
Masao Ogata
Oita University Hospital
Author Profile
Hiroki Itoh
Oita University Hospital
Author Profile

Abstract

Imatinib is used as first-line treatment for chronic myeloid leukemia (CML) even in patients with impaired renal function. We successfully used therapeutic drug monitoring to determine the dose for re-administration of imatinib in a CML patient who initiated dialysis for acute renal dysfunction associated with the initial imatinib therapy.

Peer review status:ACCEPTED

16 Nov 2020Submitted to Clinical Case Reports
11 Jan 2021Submission Checks Completed
11 Jan 2021Assigned to Editor
17 Jan 2021Reviewer(s) Assigned
21 Jan 2021Review(s) Completed, Editorial Evaluation Pending
31 Jan 2021Editorial Decision: Revise Minor
11 Apr 20211st Revision Received
21 Apr 2021Submission Checks Completed
21 Apr 2021Assigned to Editor
21 Apr 2021Review(s) Completed, Editorial Evaluation Pending
02 May 2021Editorial Decision: Accept